Syros Pharmaceuticals

Historical price data

Syros Pharmaceuticals' mission is to develop breakthrough medicines for cancer and other diseases by controlling the expression of disease-driving genes, a historically 'undruggable' target class. Its key achievement is building a proprietary gene control platform and advancing multiple candidates into clinical trials, most notably tamibarotene for RARA-positive higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). The company's strategy hinges on clinically validating its platform to unlock the therapeutic potential of modulating transcription factors, though its path is fraught with financial and clinical execution risks. Syros's future depends on demonstrating compelling efficacy and safety data to attract partnership capital or secure alternative funding.

An integrated gene control platform that maps disease-specific regulatory networks to identify and drug transcription factors and other key regulators of gene expression, a historically 'undruggable' target class.

Faces intense competition in AML/MDS from novel agents and established standards of care. Its platform competes with other approaches to 'undruggable' targets, such as protein degraders. Tamibarotene's biomarker strategy is its key near-term differentiator.